Wells Fargo
STOK icon

Wells Fargo’s Stoke Therapeutics STOK Stock Holding History

Wells Fargo’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$647K Sell
19,869
-29,716
-60% -$975K ﹤0.01% 4006
2025
Q4 		$1.57M Buy
49,585
+21,514
+77% +$647K ﹤0.01% 3629
2025
Q3 		$660K Buy
28,071
+5,066
+22% +$86.8K ﹤0.01% 4100
2025
Q2 		$261K Buy
23,005
+5,325
+30% +$50.6K ﹤0.01% 4610
2025
Q1 		$118K Buy
17,680
+894
+5% +$8.34K ﹤0.01% 5023
2024
Q4 		$185K Buy
16,786
+5,682
+51% +$69.8K ﹤0.01% 4840
2024
Q3 		$136K Sell
11,104
-283
-2% -$4.01K ﹤0.01% 4830
2024
Q2 		$154K Buy
11,387
+1,535
+16% +$20.7K ﹤0.01% 4681
2024
Q1 		$133K Buy
9,852
+1,352
+16% +$8.19K ﹤0.01% 4725
2023
Q4 		$44.7K Buy
8,500
+1,682
+25% +$7.19K ﹤0.01% 5317
2023
Q3 		$26.9K Sell
6,818
-3,689
-35% -$24.3K ﹤0.01% 5475
2023
Q2 		$112K Buy
10,507
+6,516
+163% +$69.3K ﹤0.01% 4972
2023
Q1 		$33.2K Buy
3,991
+3,891
+3,891% +$35.1K ﹤0.01% 5387
2022
Q4 		$923 Sell
100
-244
-71% -$2.54K ﹤0.01% 6209
2022
Q3 		$5K Sell
344
-231
-40% -$3.68K ﹤0.01% 5930
2022
Q2 		$8K Sell
575
-980
-63% -$14.9K ﹤0.01% 5852
2022
Q1 		$33K Sell
1,555
-6,486
-81% -$130K ﹤0.01% 5828
2021
Q4 		$193K Sell
8,041
-3,034
-27% -$72.4K ﹤0.01% 5287
2021
Q3 		$282K Buy
11,075
+6,046
+120% +$169K ﹤0.01% 4958
2021
Q2 		$169K Sell
5,029
-6,387
-56% -$226K ﹤0.01% 5096
2021
Q1 		$444K Buy
11,416
+3,386
+42% +$193K ﹤0.01% 4745
2020
Q4 		$497K Buy
8,030
+2,330
+41% +$107K ﹤0.01% 4524
2020
Q3 		$191K Sell
5,700
-4,571
-45% -$131K ﹤0.01% 4982
2020
Q2 		$245K Sell
10,271
-10,939
-52% -$260K ﹤0.01% 4795
2020
Q1 		$486K Buy
21,210
+3,180
+18% +$78.6K ﹤0.01% 4056
2019
Q4 		$510K Buy
18,030
+14,589
+424% +$367K ﹤0.01% 4347
2019
Q3 		$74K Buy
+3,441
New +$96K ﹤0.01% 5436

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wells Fargo's STOK Position: Q1 2026 in Review

Wells Fargo reduced its Stoke Therapeutics (STOK) stake by 60% in Q1 2026, selling an estimated $975K and leaving 19,869 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #4006.

Wells Fargo first reported a position in STOK in Q3 2019 and has held it in 27 quarters since. The position peaked at $1.57M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Wells Fargo held 19,869 shares of Stoke Therapeutics worth $647K as of Q1 2026.
  • Wells Fargo sold 29,716 Stoke Therapeutics shares in Q1 2026, an estimated $975K.
  • Stoke Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4006 holding.
  • Wells Fargo first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Wells Fargo's Stoke Therapeutics position peaked at $1.57M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.